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Fibroblast growth factor 21 in 
breast milk controls neonatal 
intestine function
Aleix Gavaldà-Navarro1,2, Elayne Hondares1,2, Marta Giralt1,2, Teresa Mampel1,2, 
Roser Iglesias1,2 & Francesc Villarroya1,2
FGF21 is a hormonal factor with important functions in the control of metabolism. FGF21 is found in 
rodent and human milk. Radiolabeled FGF21 administered to lactating dams accumulates in milk and 
is transferred to neonatal gut. The small intestine of neonatal (but not adult) mice highly expresses 
β-Klotho in the luminal area. FGF21-KO pups fed by FGF21-KO dams showed decreased expression 
and circulating levels of incretins (GIP and GLP-1), reduced gene expression of intestinal lactase and 
maltase-glucoamylase, and low levels of galactose in plasma, all associated with a mild decrease 
in body weight. When FGF21-KO pups were nursed by wild-type dams (expressing FGF21 in milk), 
intestinal peptides and digestive enzymes were up-regulated, lactase enzymatic activity was induced, 
and galactose levels and body weight were normalized. Neonatal intestine explants were sensitive to 
FGF21, as evidenced by enhanced ERK1/2 phosphorylation. Oral infusion of FGF21 into neonatal pups 
induced expression of intestinal hormone factors and digestive enzymes, lactase activity and lactose 
absorption. These findings reveal a novel role of FGF21 as a hormonal factor contributing to neonatal 
intestinal function via its presence in maternal milk. Appropriate signaling of FGF21 to neonate is 
necessary to ensure optimal digestive and endocrine function in developing intestine.
Milk, which is the essential source of nutrition for mammalian neonates provides major nutrients, vita-
mins, minerals and water, as well as numerous biologically active molecules, including growth factors, 
hormones and adipokines1–3. These biological active factors play important roles in maintaining neonatal 
homeostasis and supporting proper neonatal development. Some of these factors, such as leptin and 
adiponectin, are absorbed from the lumen of the gut into the neonatal circulation4. Leptin in breast 
milk is known to be involved in the control of energy balance during the post-natal period5. Other fac-
tors present in milk are believed to function in protecting the gut; for example epidermal growth factor 
present in milk facilitates the development of essential digestive functions and regulates the maturation 
of the gastrointestinal tract2,6.
The identification of the biologically active factors in milk should help improve our understanding 
and management of optimal nutrition strategies for childhood development. The enteral nutrition of 
intestinally immature neonates relies on breast milk because of unique properties and composition of 
milk7. Nutrition in early childhood has been implicated in the long-term tendencies towards obesity and 
metabolic syndrome, and epidemiological data indicate that breastfeeding protects against such met-
abolic alterations in later life3. It is considered that these protective effects may involve the effects of 
bioactive compounds found in breast milk.
Fibroblast growth factor 21 (FGF21) is a hormonal factor that plays important roles in controlling glu-
cose homeostasis and energy metabolism8. In adults, FGF21 is produced mainly in the liver; it favors glu-
cose uptake by peripheral tissues, and thus possesses anti-diabetic properties9. FGF21 is also expressed in 
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white adipose tissue (WAT), where it has been proposed to play autocrine effects10, and in brown adipose 
tissue (BAT), which releases FGF21 after thermogenic activation11. A strong regulation of the FGF21 
system has been reported in mouse neonates: FGF21 levels are very low in fetuses, but the blood levels of 
FGF21 rise dramatically after birth and the initiation of suckling; this is associated with the induction of 
hepatic FGF21 gene expression in response to fatty acids contained in milk. FGF21 has powerful effects 
in neonates, including the induction of BAT thermogenesis, which is a key process in the adaptation of 
neonates to the extrauterine environment12.
In the present study, we identified the presence of substantial amounts of FGF21 in milk, show that 
milk FGF21 is transferred to the neonatal gut, and report that milk FGF21 supports intestinal function 
in the neonate.
Results
FGF21 is present in milk. We analyzed the presence of FGF21 in human, rat and mouse milk and 
plasma samples using specific ELISA assays. As shown in Fig. 1A, FGF21 was detected in maternal milk 
at concentrations that varied by species. Similar FGF21 levels were present in plasma and milk from 
lactating mice and rats, whereas the FGF21 levels in human milk were almost half those found in the 
corresponding plasma. The FGF21 levels in human milk did not differ significantly when colostrum and 
milk at different stages of lactation were measured (Supplemental Figure 1).
Since the mammary gland is responsible for the production of some of the hormones present in 
breast milk [e.g leptin]13, we analyzed FGF21 mRNA expression in mammary gland from lactating dams. 
However, FGF21 mRNA expression was undetectable in mammary glands from mice at distinct stages of 
lactation (days 4, 8, 15 and 21 of lactation) as well as in resting mammary gland from non-lactating mice 
(Supplemental Table 1). Similarly, neither RNA from resting human mammary gland nor RNA from 
cells obtained from breastmilk, representative of mammary epithelium, showed detectable FGF21 mRNA 
expression (Supplemental Table 2), suggesting that direct production of FGF21 by mammary gland is 
unlikely to be responsible for the presence of FGF21 in milk. We then determined the plasma FGF21 
levels of lactating mice, and observed that plasma FGF21 levels were higher on days 8 and 15 of lactation, 
compared to control, non-lactating, female mice (Fig. 1B). We further analyzed the gene expression of 
FGF21 in the main FGF21-expressing tissues from lactating dams, and found that FGF21 mRNA levels 
were down-regulated in WAT and BAT but markedly induced in the liver in lactating females compared 
to control females (Fig. 1B). These results suggest that changes in liver FGF21 expression are the main 
determinants of the high FGF21 levels observed in lactating mice.
FGF21 is transferred from blood to milk in lactating dams and subsequently to neonatal gut 
in suckling pups. To test whether the FGF21 observed in maternal plasma passes to milk, lactating 
dams were intraperitoneally injected with 125I-FGF21, and the presence of 125I-FGF21 was monitored 
in plasma and milk (Fig.  1C, left). The level of 125I-FGF21 in serum peaked 2 h after injection and 
declined thereafter. Thirty-six hours after the administration of 125I-FGF21 to lactating dams, high lev-
els of 125I-FGF21 were observed in milk (Fig.  1C, left). At this point, milk 125I-FGF21 levels were in 
the range of the high levels attained in plasma just 2 h after injection. These results support the notion 
that FGF21 is transferred from the blood of lactating dams to their milk. We also studied the pres-
ence of 125I-FGF21 in the stomach, gut and plasma of suckling neonates. As shown in Fig.  1C (right), 
125I-FGF21 was detected in gastric and intestinal contents of suckling mice after 36 h of milk intake from 
125I-FGF21-treated mothers. When we resolved samples of the gut content by electrophoresis and sub-
jected them to autoradiography, our results confirmed the presence of the 23 kDa band corresponding to 
bona-fide 125I-FGF21 (Supplemental Figure 2). In contrast, the levels of 125I-FGF21 in the serum samples 
of neonates were very low (less than 5% of the stomach cpm values), indicating that the milk FGF21 is 
mainly retained in the stomach and intestine of the neonate, and is not significantly transferred to the 
systemic circulation. This suggests that FGF21 is not contributing to the circulating pool of FGF21 in the 
neonate and, if having a biological effect, it is likely to occur locally in the gut.
β-Klotho is highly expressed in the luminal area of the small intestine in neonates but not in 
adults. Considering that neonatal gastro-intestinal system may be locally exposed to milk FGF21, we 
analyzed the expression of FGF receptors (FGFRs; which mediate the effects of FGF21) in the stomach 
and small intestine during early postnatal development. We also determined the expression of β -Klotho, 
which is the auxiliary co-receptor required for specific response of cells and tissues to FGF21. The mRNA 
expression levels of FGFR1 in adult mice were somewhat lower in the stomach and intestine than in BAT, 
and those in the neonatal stomach and small intestine were similar to that in the adult small intestine 
(Fig. 2A, left). For FGFR4, the transcript levels in adult mice were lower in stomach and intestine com-
pared to the liver; and those in the neonatal stomach and intestine were somewhat lower than those in 
the corresponding adult tissues (Fig. 2A, right). The mRNA expression levels of FGFR2 and FGFR3 in 
the neonatal stomach and small intestine were lower than that in the adult small intestine (Supplemental 
Figure 3).
In adults, the mRNA levels of β -Klotho were much lower in the stomach and intestine compared to 
BAT or liver (Fig. 2B); this is consistent with the current belief that the adult gastro-intestinal system is 
not an important target of FGF2114. However, the mRNA expression of β -Klotho was markedly high in 
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Figure 1. FGF21 is present in milk and transferred to neonatal gut. (A) FGF21 protein levels in plasma 
(P) and milk (M) from mice, rats and humans. Data are means ± SEM of 6 samples in rats, 8 samples in 
mice and 20 samples in humans. (B) Plasma FGF21 levels and FGF21 mRNA expression in liver, WAT 
and BAT from female mice at days 8 and 15 of lactation, and non-lactating female controls. Statistically 
significant changes versus controls are shown as *P < 0.05, **P < 0.01. (C) Radioactivity tracing of 125I-
FGF21 in plasma and milk of lactating dams at the indicated hours after i.p. administration of 125I-FGF21 
to dams. Data are means ± SEM of TCA-precipitated material from 4 independent assays. (D) Radioactivity 
tracing of 125I-FGF21 along the stomach and small intestine of 15 day-old pups fed by 125I-FGF21-treated 
lactating dams for 36 h after treatment of the dams. Data are means ± SEM of TCA-precipitated material 
from 4 independent assays. Statistically significant differences relative to plasma levels are shown as 
*P < 0.001.
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the neonatal small intestine at both day 2 and day 8 of age. It was also high in all three sections of the 
small intestine, and was around 50–60-fold higher in the neonatal jejunum and ileum compared to the 
corresponding adult tissues (Fig. 2B).
Immunoblot assays showed that the β -Klotho protein was substantially expressed in distinct sections 
of the neonatal small intestine, but not in the adult small intestine (Fig.  2C). The levels of β -Klotho 
mRNA were compared between mucosal samples scraped from the neonatal small intestine and the 
remaining intestinal tissue. Our results indicated that β -Klotho was preferentially expressed in the neo-
natal intestinal mucosa, in parallel with cadherin-1 (a marker of the intestinal epithelium) but in opposi-
tion to actin α -2 (a marker of smooth muscle in the intestine) (Fig. 2D). We used immunocytochemistry 
to assess the preferential site(s) of β -Klotho expression, and observed an β -Klotho immunoreactive signal 
in the luminal surface of the neonatal small intestine (Fig. 2E).
Figure 2. β-Klotho is highly expressed in the luminal area of the neonatal small intestine in mice. (A) 
FGFR1 and FGFR4 mRNA levels in stomach, duodenum, jejunum, ileum and BAT or liver from 2- and 
8-day-old pups and adults. (B) β -Klotho mRNA levels in the stomach, duodenum, jejunum, ileum, BAT and 
liver from 2- and 8-day-old pups and adults. (C) Representative immunoblot analysis of β -Klotho protein 
levels in the stomach, duodenum, jejunum, ileum (40 μ g protein/lane) from 2-day-old (2d) and 8-day-old 
(8d) pups and liver (L; 15 μ g protein/lane). (D) mRNAs expression for β -Klotho, cadherin-1 and actin 
alpha-2 in total small intestine, scrapped intestinal mucosa and the remaining tissue in 15-day old neonates. 
(E) Immunohistochemical analysis of β -Klotho protein levels in ileum sections from 8 day-old neonates. 
Bars are means ± SEM of 4–6 independent samples per group. Statistically significant changes relative to 
adults (in A and B), or in mucosa versus remaining tissue for each intestine section (in D), are shown as 
*P < 0.05, **P < 0.01 and ***P < 0.001.
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Together, our data indicate that β -Klotho is specifically expressed at high levels in the small intestine 
epithelia of neonatal mice, suggesting that the neonatal small intestine may be highly responsive to 
FGF21.
The levels of incretins and digestive enzymes and blood galactose levels are decreased in 
FGF21-KO neonates fed by FGF21-KO dams. Feeding neonates by wild-type dams prevents 
intestinal alterations. To gain insight into the role of milk FGF21 in the neonatal intestine, we ana-
lyzed FGF21-knockout (KO) pups nursed by FGF21-KO dams (whose milk lacks FGF21) or by wild-type 
(WT) dams (whose milk contains FGF21), and compared them with WT pups nursed by WT dams 
or nursed by FGF21-KO dams. FGF21-KO pups fed by FGF21-KO dams showed significantly lower 
expression levels of the genes encoding the digestive enzymes lactase (Lct) and maltase glucoamylase 
(Mgam) in the ileum. A similar (but non-significant) trend was observed for sucrase isomaltase (Sis). 
We also observed reductions in the expression levels of several genes that encode intestinal hormone 
factors in the ileum, namely the proglucacon gene (Gcg, encoding glucagon-like peptide-1, GLP-1, in 
intestine), the glucose-inhibitory peptide-encoding (Gip) gene, and the cholecystokinin (Cck) gene, but 
not the peptide YY (Pyy) or FGF15 genes. When WT pups fed by FGF21-KO dams were analyzed a 
similar trend was observed, with a reduction in Mgam, Gcg and Gip levels. Multivariate analysis of the 
whole four-group experimental population indicated that the nursing genotype (i.e. presence/absence of 
FGF21 in milk) determines significantly low expression of these genes. FGF21-KO pups fed by WT dams 
showed no such down-regulation of genes encoding intestinal digestive enzymes and intestinal hormone 
factors (Fig. 3A, top).
The expression levels of several metabolic genes encoding key proteins involved in glucose and lipid 
metabolism, which are known to be highly expressed in the neonatal (but not adult) small intestine15,16 
were unaffected in FGF21-KO pups or WT pups regardless of whether they were fed by FGF21-KO 
or WT dams (Fig. 3A, bottom). Furthermore, none of the gene expression changes found in the small 
intestine of neonatal FGF21-KO mice nursed by FGF21-KO dams were observed in the intestine of 
FGF21-KO adult mice (Supplemental Figure 4).
Consistent with the above findings, the circulating levels of the incretins, GLP-1 and GIP, tended to 
be lowered in FGF21-KO neonates, but were rescued when these pups were fed by WT dams (Fig. 3B). 
In WT pups fed FGF21-KO dams only GIP levels were similarly lowered. No significant reduction was 
observed in the lactase activity of FGF21-KO pups fed by FGF21-KO. However, feeding FGF21-KO pups 
with FGF21-containing milk induced the lactase activity in the small intestine. Multivariate analysis 
revealed that the nursing dam’s genotype is associated to statistically significant reduction in lactase 
activity in duodenum and jejunum (Fig. 3C).
To estimate the consequences of intestine changes on lactose digestion performance we analyzed 
galactose levels in pups’ blood. Results indicated a significant reduction in galactose levels in FGF21-KO 
pups fed by dams lacking FGF21 in milk either in WT pups or in FGF21-KO pups (Fig. 3D).
To further examine the potential action of milk FGF21 on the neonatal small intestine, we determined 
ERK1/2 phosphorylation levels in our experimental setting. FGF21-KO pups fed WT (FGF21-containing) 
milk showed a significant induction of ERK1/2 phosphorylation compared to FGF21-KO pups fed by 
FGF21-KO dams (Fig. 3E), suggesting that FGF21 in milk enhances ERK1/2 phosphorylation.
Based on these results, we conclude that feeding FGF21-KO pups with FGF21-lacking milk alters 
the pups’ intestinal enzyme and hormonal profile, but that this can be prevented by feeding KO pups 
with FGF21-containing milk. WT pups fed milk lacking FGF21 show similar, although somewhat more 
moderate, alterations. Our characterization of the nutritional, biochemical and hormonal compositions 
of the milk from FGF21-KO dams did not reveal any major difference relative to WT milk (Supplemental 
Table 3). We therefore propose that the FGF21 present in milk from WT dams may act on the neonatal 
intestine, thereby preventing the alterations observed in FGF21-KO pups.
The physiological, biochemical and hormonal parameters of neonates were determined under distinct 
maternal nursing conditions. We found that FGF21-KO pups delivered by FGF21-KO dams did not 
differ in body weight at birth relative to WT pups. As lactation proceeded, however, FGF21-KO pups 
nursed by FGF21-KO dams showed moderate (but significant), reductions in body weight compared 
to WT pups (Fig. 4A). This was a transient phenomenon, as FGF21-KO mice that had been nursed by 
FGF21-KO dams did not show significant differences in body weight relative to controls after weaning, 
neither males nor females. FGF21-KO pups nursed by WT dams did not show this neonatal reduction 
in body weight (Fig. 4B). When WT pups were nursed by dams lacking FGF21 in milk, there was also 
a transient reduction in body weight, which, in this case, was already normalized at day 21 after birth.
Assessment of biochemical parameters in this experimental setting didn’t reveal significant changes in 
single group-based comparisons. However, multivariate analysis indicated that glucose and triglyceride 
levels were significantly reduced in association with nursing dam’s genotype but not with pup’s genotype 
(Supplemental Table 4).
FGF21 induces the gene expression of intestinal hormones and digestive enzymes in neona-
tal intestine explants. To assess the direct effects of FGF21 in the neonatal intestine, small intestine 
explants from 8-day-old pups were treated with FGF21 in vitro. Our results revealed that FGF21 rapidly 
and significantly induced the phosphorylation of ERK1/2, which is the canonical intracellular mediator 
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Figure 3. Effects of FGF21-KO lactation on the neonatal intestine. Data are shown from wild-type 
(WT) pups fed by WT dams, FGF21-KO pups fed by FGF21-KO dams, FGF21-KO pups fed by WT dams 
and FGF21-WT pups fed by KO dams, from day 1 after birth to postnatal day 8. (A) Transcript levels in 
the ileum. (B) Plasma levels of GLP-1, GIP and PYY. (C) Lactase activity in the ileum. (D) Plasma levels 
of galactose. (E) Levels of ERK1/2 phosphorylation (representative immunoblot, 40 μ g protein/lane, left; 
quantification of the immunoblot signal intensity, right). Bars are means ± SEM of 5 independent samples 
per group, each one being pooled samples from 4–5 independent litters. Statistically significant changes 
versus WT pups fed by WT dams are shown as *P < 0.05, **P < 0.01 and those between FGF21-KO pups 
fed by WT and those fed by FGF21-KO dams are shown as #P < 0.05, ##P < 0.01. Statistically significant 
changes between WT pups fed by KO dams and other groups are shown as ΦP < 0.05. Statistically significant 
changes between pups fed by WT dams and KO dams, retrieved by two-factor ANOVA analysis, are shown 
as $P < 0.05, $$P < 0.01 and $$$P < 0.001.
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of the intracellular effects of FGF21 (Fig. 5A). Moreover, exposure of neonatal small intestine explants 
to FGF21 significantly induced the expression of the intestinal hormone factor-encoding genes Gcg, Gip 
and Cck, as well as that of the gene encoding sucrase isomaltase (Sis) (Fig. 5B).
Oral infusion of FGF21 to neonatal gut induces the gene expression of intestinal hormones 
and increases intestinal lactase activity and lactose absorption. To confirm these findings 
above about direct effects of FGF21 on neonatal intestine using an “in vivo” approach, we intragastri-
cally infused to 8 day-old FGF21-KO pups with FGF21. Gene expression analysis in the small intestine 
revealed that FGF21 significantly induced the expression of Gcg, Gip and Lct genes (Fig. 6A). Moreover, 
lactase enzymatic activity was increased significantly by FGF21 gavage (Fig.  6B). To obtain a dynamic 
assessment of the effects of FGF21 on lactose absorption, we determined the effects of intragastrically 
infused FGF21 on the rate of 14C-lactose conversion to 14C-CO2 in neonatal mice. We found that 
FGF21 increased significantly the rate of lactose absorption and further metabolization (Fig. 6C). These 
findings confirmed the capacity of FGF21 to act directly in the lumen of the neonatal intestine and tar-
geting intestinal hormones and digestive enzymes, and promoting lactose digestion.
Discussion
In recent years, FGF21 has emerged as an important hormonal factor that has pleiotropic effects in meta-
bolic regulation9. It is also important in neonatal life, as evidenced by the milk-intake-triggered induction 
of expression and FGF21 levels in newborn mice. High levels of FGF21 in neonatal mouse blood trig-
ger important adaptations in the newborn, such as thermogenic activation of BAT12. The present study 
reveals that FGF21 is present in breast milk. This milk FGF21 does not contribute to systemic levels 
of FGF21 in mouse neonates; instead, it appears to act locally on the mouse neonatal intestine where 
it regulates the expression and activity of digestive enzymes and the synthesis and release of intestinal 
hormone factors, including the incretins GLP-1 and GIP1.
The presence of bioactive molecules in maternal milk has been increasingly recognized over the past 
few decades1. Milk proteins are resistant to degradation in the stomach; this is due to the low acidity of 
the infant stomach, and the protective (i.e. anti-proteolytic) environment that is formed by milk compo-
nents as they enter the stomach17,18. Several growth factors are known to be transferred from maternal 
Figure 4. Body weight of FGF21-KO mice nursed by FGF-KO dams and WT mice nursed by WT 
dams and effects of nursing of FGF21-KO mice by WT dams on neonatal body weight. (A) Weights of 
neonatal WT pups nursed by WT dams and FGF21-KO pups nursed by FGF21-KO dams were registered 
periodically during 4 months. (B) Weights of WT pups nursed by WT or by KO dams and FGF21-KO 
pups nursed by FGF21-KO or by WT dams were registered at days 8 and 21. Results are the means + SEM 
from 5–6 independent litters. For adults, data are means of 10 individuals from, at least, 2 independent 
litters. Statistically significant changes versus WT pups fed by WT dams are shown as *P < 0.05, **P < 0.01 
and those between FGF21-KO pups fed by WT and those fed by FGF21-KO dams are shown as #P < 0.05, 
##P < 0.01. Statistically significant changes between pups fed by WT dams and KO dams, retrieved by two-
factor ANOVA analysis, are shown as $P < 0.05, $$P < 0.01 and $$$P < 0.001.
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Figure 5. FGF21 induces the gene expression of intestinal hormones and digestive enzymes in neonatal 
intestine explants. (A) Eight-day-old mouse small intestine explants were treated with 10 nM FGF21 for 
10 min and 20 min, and the levels of phosphorylated ERK1/2 were assessed. A representative immunoblot 
is shown (40 μ g protein/lane; C, control; F, FGF21). (B) Eight-day-old mouse small intestine explants were 
treated with 10 nM FGF21 for 3 h, and transcript levels were assessed.
Figure 6. Oral infusion of FGF21 to neonatal gut induces the gene expression of intestinal hormones 
and increases intestinal lactase activity and lactose absorption. (A) Eight-day-old pups were subjected to 
intragastric infusion of 100 ng/ml FGF21 and after 4 h transcript levels were assessed. (B) Lactase activity 
was determined in the ileum from eight-day-old pups after 4 h of an intragastrically infusion with 100 ng/
ml FGF21. (C) Lactase absorption rate was assessed by administering 14C-lactose in eight-day-old pups 4 h 
after 100 ng/ml FGF21 infusion and quantifying the breathed out radiolabeled CO2. Bars are means ± SEM 
of 4 independent experiments. Statistical significance of differences versus controls are shown as *P < 0.05, 
**P < 0.01.
www.nature.com/scientificreports/
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milk to the neonatal intestine, where they play important roles in promoting intestinal maturation. 
Adipokines, such as leptin and adiponectin, have also been found in maternal milk, and there is evidence 
that contribute to the systemic levels of these factors in neonates4,19. Here, we establish that FGF21 is 
among the endocrine factors that confer the important properties of breast milk and contribute to the 
maturation of the neonatal gastro-intestinal system, at least in the current rodent model. Maternal blood, 
rather than the mammary gland, appears to be the main source of milk FGF21; this is similar to previous 
findings for EGF20 and IGF-II21, but contrasts with those for leptin and adiponectin13,22. Consistent with 
a previous report23, we observed high blood FGF21 levels in lactating dams. This is likely to favor the 
substantial transfer of FGF21 to milk.
The small intestine expresses substantial levels of FGF receptors, mainly FGFR1, which can mediate 
responsiveness to FGFs. We found that β -Klotho, the co-receptor that mediates specific responsiveness 
to FGF21, is highly expressed in the luminal area of the neonatal (but not adult) small intestine. Due 
to this specific developmental regulated expression of β -Klotho, the neonatal gut becomes target of the 
effects of FGF21, as evidenced by the induction of ERK1/2 phosphorylation in the intestines of pups fed 
FGF21-containing milk and in FGF21-treated neonatal intestine explants “in vitro”.
A subset of the intestinal digestive enzymes, including lactase, sucrase isomerase and maltase glu-
coamylase, appears to be target of FGF21 in the neonatal intestine. However, the gene expression and 
activities of these enzymes were affected to different extent by our experimental manipulations to assess 
the effects of FGF21. In any case, dynamic assessment of the effects of FGF21 on lactose digestion and 
further metabolization as well as galatose levels revealed a positive action of FGF21 promoting lactose 
absorption. A second important set of genes that appear to be regulated by FGF21 in the neonatal intes-
tine include the intestinal hormonal factors GLP-1 and GIP.
The systemic consequences of our experimental alterations in pups were moderate. FGF21-KO pups 
pups as well as WT pups nursed by FGF21-KO dams are viable, and body weight alterations are transient. 
However, the rescue of body weight reduction when FGF21-KO pups were fed by WT dams indicates 
that milk FGF21 may be relevant for optimal neonate development. The moderate, but significant, reduc-
tion in blood glucose and triglyceride levels associated with the lack of FGF21 in maternal milk is likely 
to reflect a mild alteration in the nutritional status of pups consistent with low body weight. Although 
non-detected alterations in the lactation performance of FGF21-KO dams, unrelated to the absence of 
FGF21 in milk, cannot be totally ruled out, the evidence of direct effects of FGF21 in neonatal intestine 
reported here, strongly suggest a role for milk FGF21. Perhaps, as in other gene-invalidation models, 
other factors present in milk could elicit homeostatic, compensatory, processes to moderate the impact 
of the lack of FGF21 in milk. Given the growing awareness of the impact of early nutritional and hor-
monal disturbances on later adult physiopathology both in rodents and humans24, additional research 
is warranted to examine whether inappropriate FGF21 signaling in the neonatal gut may contribute to 
later adult susceptibility to metabolic alterations. Although extrapolation of data from rodent models 
to humans should be done with caution, future studies should also examine the possible contribution 
of FGF21 signaling the neonatal gut to the optimal action of breast milk for enteral nutrition in highly 
premature infants with intestinal immaturity25.
In summary, we herein report a novel biological role for FGF21 as a hormonal factor present in 
milk and involved in controlling neonatal intestine function (Fig. 7). Further studies will be required to 
confirm these findings in human neonates and therefore to establish their potential implications in the 
biomedical context of neonatal counseling, the importance of maternal breast feeding and the need to 
optimize biotechnological formula designs to fulfill the complexities of optimal milk composition and 
mimic the properties of breast milk.
Methods
Animals. Mice were maintained under standard conditions of light (12 h light/12 h dark cycle) and 
temperature (21 ± 1 °C); the care and use of mice was performed in accordance with the European 
Community Council Directive 86/609/EEC and all experimental procedures were approved by the 
Institutional Animal Care and Use Committee of the University of Barcelona.
Acquisition and analysis of rodent milk. Milk samples from dams were collected by manual 
milking from anesthetized 15-day lactating mice and rats. FGF21 protein levels in milk and plasma 
were determined by ELISA (BioVendor). Milk analysis included measurement of triglycerides and lac-
tose (both from Sigma-Aldrich), protein (Bio-Rad), individual fatty acid composition26, adiponectin 
(Invitrogen), leptin (Millipore).
Measurements in human breast milk. Human FGF21 protein levels were measured in milk and 
serum (BioVendor) obtained from 4 (colostrum), 4 (transitional milk) and 14 (mature milk) healthy 
women between 27–37 years of age, after obtaining the informed consent from all subjects. For analysis 
of lactating mammary gland cell RNA, 5 milk samples (5 ml) were collected using a manual pump under 
aseptic conditions, stored at 4 °C, and processed within 6 hours for isolation of cells following a previ-
ously described method27 (See Supplemental Methods for further details). The studies were performed 
in accordance with the approved guidelines and procedures. The Bioethics Committee at the University 
of Barcelona, Spain, approved the human studies.
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125I-FGF21 tracing. Fifteen days after parturition, lactating mice were intraperitoneally (i.p.) injected 
with 5 μ Ci of 125I-FGF21 (Phoenix Europe). Blood samples were obtained via direct puncture of the 
saphenous vein at 2, 8, 12 and 36 h after injection; milk was obtained at 36 h after injection. Neonatal 
plasma, stomach and total small intestine samples were obtained. The 125I-FGF21 was separated from free 
125I by tricholoroacetic acid (TCA) protein precipitation, and radioactivity was assessed using a γ -counter 
(Packard Cobra II).
Figure 7. Summary of the action of maternal milk FGF21 on controlling the function of neonatal 
intestine. In lactating dams, lactation induces hepatic production of FGF21, which is transferred from 
plasma to milk and reaches neonatal intestine. FGF21 acts on the complex FGFR-β -Klotho present in the 
intestinal epithelial cells of neonates and promotes the production of intestinal peptides (e.g. GLP-1 or 
GIP) and intestinal digestive enzymes, such as lactase. Mice photographs and drawings were performed by A. 
Gavaldà-Navarro.
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Studies in neonatal mice and animal experimental designs. When indicated, we used FGF21-/- 
(FGF21-KO) mice (B6N;129S5-Fgf21tm1Lex/Mmcd, from the Mutant Mouse Regional Resource Centre, 
an NCRR-NIH-funded strain repository, donated to the MMRRC by Genentech, Inc) that had been 
backcrossed to the C57/BL6 background28.
For cross-feeding experiments, WT or FGF21-KO adult mice were mated. At the time of simultaneous 
deliveries (maximum variability in delivery time, 12 h) maximum), the following experimental groups 
were established: WT pups fed by WT dams, KO pups fed by KO dams; KO pups fed by WT dams, 
and WT pups fed by KO dams. All litters were adjusted to 7–8 pups and were fed by a non-progenitor 
dam, even for experiments in which the maternal and neonatal genotypes were the same. After 8 days 
of lactation, pups were killed by decapitation, blood was collected, plasma was obtained and tissues were 
collected and frozen for further processing. Blood glycemia (Accutrend®), plasma galactose (Abcam), 
NEFA and ketone bodies (Wako), triglycerides and glycerol (Sigma-Aldrich) were determined.
For oral infusion of FGF21, 8 day-old FGF21-KO pups were orally infused with 100 μ l of 100 ng/
ml FGF21 dissolved with 20% Intralipid™ (Fresenius Kabi) or 20% Intralipid™ alone (vehicle), using a 
0,038” Intramedic® polyethylene tube introduced into the stomach. After 4 h after administration, the 
pups were killed by decapitation, and tissues were collected and frozen for further processing.
Intestinal explant incubation. Sections of jejunum (0.5-cm) from 8-day old pups were cut longi-
tudinally and incubated with DMEM with or without 10 nM mouse recombinant FGF21 (BioVendor 
R&D). At the indicated times, tissue and media were collected for further analysis.
RNA isolation, cDNA synthesis, and real-time PCR. Total RNA was isolated from rodent samples 
(tissues, scraped intestinal mucosa, and intestine explants), as well as from cells that had been isolated 
from human breast milk using a previously described method27. Independent samples of total RNA 
from human mammary gland were obtained from Clontech and AMS Biotechnology. RNA was prepared 
using a column-affinity based methodology (Macherey-Nagel). Total RNA (500 ng) was transcribed 
into cDNA using Multiscribe reverse transcriptase and random-hexamer primers (TaqMan Reverse 
Transcription Reagents; Applied Biosystems/Life Technologies). For quantitative analysis of mRNA 
expression, TaqMan quantitative real-time polymerase chain reaction (qPCR) was performed using a 
7500 Real-Time PCR System (Applied Biosystems) and a final volume of 20 μ l containing Platinum 
Quantitative PCR SuperMix-UDG with ROX reagent (Invitrogen) and specific primer pair/probe sets 
obtained from Applied Biosystems/Life Technologies. The relative mRNA expression levels of the differ-
ent genes were normalized with respect to that of the 18S rRNA or Ppia mRNA (endogenous controls) 
using the comparative (2−ΔCT) method. Transcript levels were considered undetectable when the CT 
value was ≥ 40 under these experimental conditions.
Western blot analysis. Tissue protein extracts, milk and plasma were analyzed by Western blot-
ting using standard procedures. The utilized primary antibodies were directed against Phospho-p44/42 
MAPK (P-Erk1/2) (Thr202/Tyr204) and p44/42 MAPK (Erk1/2) (both from Cell Signaling), β -Klotho 
(Abcam), FGF21 (Santa Cruz Biotechnology) and β -actin (Sigma-Aldrich). Immunoreactive signals were 
obtained using an enhanced chemiluminescence HRP substrate (Millipore).
Immunohistochemical detection of β-Klotho. Intestinal segments were collected, fixed with 4% 
formalin for 24 h, and subsequently stored in ethanol 70% at 4 °C until paraffin infiltration was per-
formed. Paraffin-embedded tissues were divided into transverse and longitudinal sections, and mounted 
on glass slides. Samples were incubated overnight at 4 °C with an anti-β -Klotho antibody (LifeSpan 
BioSciences), incubated with an ABC complex-conjugated secondary antibody, and treated with DAB for 
visualization of results. Finally, the samples were stained with hematoxylin 50x optical microphotographs 
were obtained.
Quantification of intestinal peptides in plasma. The plasma concentrations of glucagon-like pep-
tide 1 (GLP-1), gastric inhibitory peptide (GIP) and peptide YY (PYY) were determined using multiplex 
assays (Millipore Corporation).
Lactase activity. Protein extracts were obtained from neonatal duodenum, jejunum and ileum, and 
lactase activity was assayed using a slight modification of the method described by Dahlqvist, A29.
Lactose absorption rate measurement. Lactose absorption rate was assessed by quantifying the 
exhalation of 14CO2 produced from the oxidation of 14C-lactose infused to gut, following a previously 
described method30 adapted to mouse neonates. Briefly, after 4 hours of oral infusion of 100 ng/ml 
FGF21, pups were orally infused with 2.5 μ Ci 14C-lactose (Hartmann Analytic) dissolved in 100 μ l of 
water. Pups were maintained in a chamber which contained a 6 cm2 Whatman® paper impregnated with 
phenylethylamine (Sigma). CO2 paper traps were collected every 30 minutes during 3 hours. CO2 paper 
traps were counted using a Packard 2100TR TriCarb Liquid Scintillation Counter and the linear rate of 
14CO2 counts appearance was calculated.
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Statistical Analysis. All results are expressed as means ± SEM, and differences were compared using 
the unpaired t-test, one-way analysis of variance (ANOVA) with Tukey’s Multiple Comparison Test, or 
two-way ANOVA with Bonferroni post-test, as appropriate.
References
1. Grosvenor, C. E., Picciano, M. F. & Baumrucker, C. R. Hormones and growth factors in milk. Endocr Rev. 14, 710–728 (1993).
2. Dvorak, B. Milk epidermal growth factor and gut protection. J. Pediatr. 156(Suppl), S31–S35 (2010).
3. Savino, F., Benetti, S., Liguori, S. A., Sorrenti, M. & Cordero Di Montezemolo, L. Advances on human milk hormones and 
protection against obesity. Cell Mol Biol. 59, 89–98 (2013).
4. Savino, F. & Liguori, S. A. Update on breast milk hormones: leptin, ghrelin and adiponectin. Clin Nutr. 27, 42–47 (2008).
5. Picó, C. et al. Role of leptin present in maternal milk in the control of energy balance during the post-natal period. Genes Nutr. 
2(1), 139–141 (2007).
6. Wagner, C. L., Taylor, S. N. & Johnson, D. Host factors in amniotic fluid and breast milk that contribute to gut maturation. Clin 
Rev Allergy Immunol. 34, 191–204 (2008).
7. Grand, R. J., Sutphen, J. L. & Montgomery, R. K. The immature intestine: implications for nutrition of the neonate. Ciba Found 
Symp. 70, 293–311 (1979).
8. Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 115, 1627–1635 (2005).
9. Adams, A. C. & Kharitonenkov, A. FGF21: The center of a transcriptional nexus in metabolic regulation. Curr Diabetes Rev. 8, 
285–293 (2012).
10. Dutchak, P. A. et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell. 
148, 556–567 (2012).
11. Hondares, E. et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem. 286, 
12983–12990 (2011).
12. Hondares, E. et al. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to 
thermogenic activation of neonatal brown fat. Cell Metab. 11, 206–212 (2010).
13. Smith-Kirwin, S. M. et al. Leptin expression in human mammary epithelial cells and breast milk. J Clin Endocrinol Metab. 83, 
1810–1813 (1998).
14. Fon Tacer, K. et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. 
Mol Endocrinol 24, 2050–2064 (2010).
15. Asins, G., Serra, D., Arias, G. & Hegardt, F. G. Developmental changes in carnitine palmitoyltransferases I and II gene expression 
in intestine and liver of suckling rats. Biochem J 306, 379–384 (1995).
16. Serra, D. et al. The expression of mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme-A synthase in neonatal rat intestine and 
liver is under transcriptional control. Eur J Biochem. 237, 16–24 (1996).
17. Lonnerdal, B. Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr. 77, 1537S–1543S (2003).
18. Hamosh, M. Digestion in the newborn. Clin Perinatol. 23, 191–209(1996).
19. Newburg, D. S., Woo, J. G. & Morrow, A. L. Characteristics and potential functions of human milk adiponectin. J Pediatr. 
156(Suppl), S41–S46 (2010).
20. Brown, K. D., Blakeley, D. M., Fleet, I. R., Hamon, M. & Heap, R. B. Kinetics of transfer of 125I-labelled epidermal growth factor 
from blood into mammary secretions of goats. J Endocrinol 109, 325–332 (1986).
21. Prosser, C. G., Fleet, I. R., Davis, A. J. & Heap, R. B. Mechanism of secretion of plasma insulin-like growth factor-I into milk of 
lactating goats. J Endocrinol. 131, 459–466 (1991).
22. Ohtani, Y. et al. Gene expression and hormonal regulation of adiponectin and its receptors in bovine mammary gland and 
mammary epithelial cells. Anim Sci J 82, 99–106 (2011).
23. Schoenberg, K. M. et al. Plasma FGF21 is elevated by the intense lipid mobilization of lactation. Endocrinology 152, 4652–4661 
(2011).
24. Brands, B., Demmelmair, H., Koletzko, B. Early Nutrition Project. How growth due to infant nutrition influences obesity and 
later disease risk. Acta Paediatr. 103, 578–585 (2014).
25. Lucas, A. & Cole, T. J. Breast milk and neonatal necrotizing enterocolitis. Lancet. 336, 1519–1523 (1990).
26. Lepage, G. & Roy, C. C. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res. 27, 114–120 (1986).
27. Hassiotou, F. et al. Breastmilk is a novel source of stem cells with multilineage differentiation potential. Stem Cells. 30, 2164–2174 
(2012).
28. Planavila, A. et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4, 2019. doi: 10.1038/
ncomms3019 (2013).
29. Dahlqvist, A. Assay of intestinal disaccharidases. Scand J Clin Lab Invest 44, 169–172 (1984).
30. Salmon, P. R., Read, A. E. & McCarthy, C. F. An isotope technique for measuring lactose absorption. Gut 108, 685–689 (1969).
Acknowledgments
We thank the human milk donors who helped make this study possible. We are grateful to Dr López-
Tejero, Dr ML Seoane, Dr Joan C Domingo and L. López for providing technical advice. This work was 
supported by MINECO (Grant SAF2011-2636), Recercaixa Foundation, Instituto Danone and Generalitat 
de Catalunya (Grant 2009SGR00284), Spain. The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
Author Contributions
The experiments were conceived and designed by and F.V., R.I. and T.M.; experiments were performed by 
A.G.-N., E.H., R.I., M.G. and T.M. Specifically, E.H. and M.G. performed analytical procedures in milk; 
E.H., R.I. and T.M. performed tracing experiments; A.G.-N. and R.I. performed experiments involving 
FGF21-knockout experimental designs; and A.G.-N. performed experiments involving in vitro and 
in vivo administration of FGF21. All authors discussed the data and elaborated conclusions. Figure 7 is 
original and was drawn by A.G.-N. The paper was written by F.V.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
www.nature.com/scientificreports/
13Scientific RepoRts | 5:13717 | DOi: 10.1038/srep13717
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Gavaldà-Navarro, A. et al. Fibroblast growth factor 21 in breast milk controls 
neonatal intestine function. Sci. Rep. 5, 13717; doi: 10.1038/srep13717 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. The 
images or other third party material in this article are included in the article’s Creative Com-
mons license, unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to reproduce 
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
